{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:14:49Z","timestamp":1787721289623,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38465-z","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:33:03Z","timestamp":1770154383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and preliminary efficacy of adding tocilizumab to cisplatin\/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1\/2 clinical trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Taher","family":"Al-Tweigeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Tulbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshari","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusnem","family":"El Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura N.","family":"Alraouji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kauser","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adher","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelilah","family":"Aboussekhra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"38465_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/bjc.2017.379","volume":"118","author":"SM Reddy","year":"2018","unstructured":"Reddy, S. M. et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br. J. Cancer. 118 (1), 17\u201323 (2018).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"38465_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J. J., Bian, X. W. & Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22 (1), 61 (2020).","journal-title":"Breast Cancer Res."},{"key":"38465_CR3","doi-asserted-by":"crossref","unstructured":"Wu, Q., Siddharth, S. & Sharma, D. Triple negative breast cancer: A mountain yet to be scaled despite the triumphs. Cancers (Basel) 13(15), 3697 (2021).","DOI":"10.3390\/cancers13153697"},{"issue":"10087","key":"38465_CR4","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 389 (10087), 2430\u20132442 (2017).","journal-title":"Lancet"},{"key":"38465_CR5","doi-asserted-by":"crossref","unstructured":"Vagia, E., Mahalingam, D. & Cristofanilli, M. The landscape of targeted therapies in TNBC. Cancers (Basel) 12(4), 916 (2020).","DOI":"10.3390\/cancers12040916"},{"issue":"9","key":"38465_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N Engl. J. Med. 382(9), 810\u2013821 (2020).","journal-title":"N Engl. J. Med."},{"issue":"21","key":"38465_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl. J. Med. 391(21), 1981\u20131991 (2024).","journal-title":"N Engl. J. Med."},{"issue":"11","key":"38465_CR8","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/0008-5472.CAN-12-4524-T","volume":"73","author":"ZC Hartman","year":"2013","unstructured":"Hartman, Z. C. et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73(11), 3470\u20133480 (2013).","journal-title":"Cancer Res."},{"issue":"1","key":"38465_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","volume":"9","author":"Z Guo","year":"2023","unstructured":"Guo, Z. et al. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell. Death Discov. 9 (1), 6 (2023).","journal-title":"Cell. Death Discov"},{"issue":"45","key":"38465_CR10","doi-asserted-by":"publisher","first-page":"30962","DOI":"10.1074\/jbc.M114.594044","volume":"289","author":"SF Hendrayani","year":"2014","unstructured":"Hendrayani, S. F., Al-Khalaf, H. H. & Aboussekhra, A. The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent Up-regulation of the RNA-binding protein AUF1. J. Biol. Chem. 289 (45), 30962\u201330976 (2014).","journal-title":"J. Biol. Chem."},{"key":"38465_CR11","doi-asserted-by":"publisher","first-page":"903800","DOI":"10.3389\/fonc.2022.903800","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. IL-6: the link between inflammation, immunity and breast cancer. Front. Oncol. 12, 903800 (2022).","journal-title":"Front. Oncol."},{"issue":"12","key":"38465_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara, M. et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 5 (12), 1731\u20131740 (2005).","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"38465_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","volume":"47","author":"H Korkaya","year":"2012","unstructured":"Korkaya, H. et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2\u2009+\u2009breast cancer by expanding the cancer stem cell population. Mol. Cell. 47 (4), 570\u2013584 (2012).","journal-title":"Mol. Cell."},{"issue":"10","key":"38465_CR14","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1158\/1078-0432.CCR-15-1139","volume":"22","author":"FT Liu","year":"2016","unstructured":"Liu, F. T. et al. CD126 and targeted therapy with tocilizumab in chronic lymphocytic leukemia. Clin. Cancer Res. 22(10), 2462\u20132469 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"38465_CR15","doi-asserted-by":"publisher","first-page":"22822","DOI":"10.18632\/oncotarget.4477","volume":"6","author":"D Mochizuki","year":"2015","unstructured":"Mochizuki, D. et al. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget 6(26), 22822\u201322835 (2015).","journal-title":"Oncotarget"},{"issue":"15","key":"38465_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1101\/gad.262642.115","volume":"29","author":"R Rodriguez-Barrueco","year":"2015","unstructured":"Rodriguez-Barrueco, R. et al. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-\/HER2\u2009+\u2009breast cancers. Genes Dev. 29 (15), 1631\u20131648 (2015).","journal-title":"Genes Dev."},{"issue":"17","key":"38465_CR17","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","volume":"15","author":"S Shinriki","year":"2009","unstructured":"Shinriki, S. et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin. Cancer Res. 15 (17), 5426\u20135434 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"38465_CR18","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/carcin\/bgab102","volume":"42","author":"N Al-Jomah","year":"2021","unstructured":"Al-Jomah, N., Al-Mohanna, F. H. & Aboussekhra, A. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3\/AUF1 pathway. Carcinogenesis 42(12), 1439\u20131448 (2021).","journal-title":"Carcinogenesis"},{"issue":"9","key":"38465_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mc.23234","volume":"59","author":"NN Alraouji","year":"2020","unstructured":"Alraouji, N. N. et al. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol. Carcinog. 59 (9), 1041\u20131051 (2020).","journal-title":"Mol. Carcinog."},{"key":"38465_CR20","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.2147\/DDDT.S253961","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang, H. & Mao, X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des. Devel Ther. 14, 2423\u20132433 (2020).","journal-title":"Drug Des. Devel Ther."},{"issue":"28","key":"38465_CR21","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25 (28), 4414\u20134422 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"38465_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12032-009-9251-7","volume":"27","author":"TA Al-Tweigeri","year":"2010","unstructured":"Al-Tweigeri, T. A. et al. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin\/docetaxel in locally advanced breast cancer. Med. Oncol. 27 (3), 571\u2013577 (2010).","journal-title":"Med. Oncol."},{"issue":"4","key":"38465_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin. Cancer Res. 27(4), 975\u2013982 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"38465_CR24","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/bcr3231","volume":"14","author":"T Byrski","year":"2012","unstructured":"Byrski, T. et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 14 (4), R110 (2012).","journal-title":"Breast Cancer Res."},{"issue":"3","key":"38465_CR25","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1002\/onco.13574","volume":"26","author":"Y Yuan","year":"2021","unstructured":"Yuan, Y. et al. Phase II trial of neoadjuvant carboplatin and Nab-Paclitaxel in patients with triple-negative breast cancer. Oncologist 26(3), e382\u2013e93 (2021).","journal-title":"Oncologist"},{"key":"38465_CR26","doi-asserted-by":"crossref","unstructured":"Porta, F. M. et al. Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods. J. Pers. Med. 13(7), 1176 (2023).","DOI":"10.3390\/jpm13071176"},{"issue":"7","key":"38465_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/jpm13071176","volume":"13","author":"FM Porta","year":"2023","unstructured":"Porta, F. M. et al. Immune biomarkers in Triple-Negative breast cancer: improving the predictivity of current testing methods. J. Personalized Med. 13 (7), 1176 (2023).","journal-title":"J. Personalized Med."},{"issue":"10","key":"38465_CR28","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf, E. M. et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann. Oncol. 26 (10), 2141\u20132149 (2015).","journal-title":"Ann. Oncol."},{"key":"38465_CR29","doi-asserted-by":"publisher","first-page":"5535486","DOI":"10.1155\/2021\/5535486","volume":"2021","author":"T Alsulaim","year":"2021","unstructured":"Alsulaim, T., Alhassan, N., Khalil, H. & Almutlaq, A. Tocilizumab effect on lipid profile in correlation to cardiovascular events: A retrospective cohort study. Int J Rheumatol. 2021, 5535486 (2021).","journal-title":"Int J Rheumatol."},{"key":"38465_CR30","doi-asserted-by":"crossref","unstructured":"Hoffman, E. et al. Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int. J. Mol. Sci. 20(18), 4633 (2019).","DOI":"10.3390\/ijms20184633"},{"issue":"1","key":"38465_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","volume":"26","author":"V Volarevic","year":"2019","unstructured":"Volarevic, V. et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci. 26 (1), 25 (2019).","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"38465_CR32","doi-asserted-by":"publisher","first-page":"104088","DOI":"10.1016\/j.esmoop.2024.104088","volume":"10","author":"JY Blay","year":"2025","unstructured":"Blay, J. Y. et al. Anti-IL-6R Ab Tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers. ESMO Open. 10 (1), 104088 (2025).","journal-title":"ESMO Open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38465-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:06:15Z","timestamp":1771542375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38465"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38465-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committee at King Faisal Specialist Hospital and Research Centre (SCTR 19111002) and retrospectively by ISRCTN (ISRCTN50182475). Informed consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"7029"}}